CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 83 enrolled
Drug / intervention
Sitagliptin +1 moredrug
Likely dose
Sitagliptin 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01186562
NCT01186562Phase 4Completed
CompareCT.gov

A Double-Blind, Randomized, Placebo Controlled Intervention Study to Assess the Impact of Sitagliptin 100 mg/Day for 1 Year on Insulin Independence Following Pancreatectomy and Autoislet Transplantation

University of Minnesota·interventional·Posted Aug 23, 2010·Updated May 31, 2017

In Brief

A Phase 4 clinical trial evaluating Sitagliptin and Placebo for Pancreatitis and Diabetes. Completed, enrolled 83 participants across 1 site.

Detailed Summary

The purpose of the study is to test the effects of sitagliptin on the need for insulin (the hormone that lowers blood sugars) by patients who receive a pancreatectomy and islet autotransplant for chronic pancreatitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatitis, Diabetes
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 23, 2010
Enrollment StartAug 1, 2010
Primary CompletionJul 1, 2015
Study CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 15.9 years ago

Interventions

Sitagliptindrug

100 mg PO daily

Placebodrug

Placebo